Pedro Calomeni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pedro Calomeni has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Adriano Dias Dourado Oliveira
Hospital Santa Izabel, Brasil
2 shared publicationsAlexandre Abizaid
Universidade de São Paulo, Brasil
2 shared publicationsAntenor Lages Fortes Portela
Associação Piauiense de Combate ao Câncer, Brasil
2 shared publicationsAugusto Celso Lopes
Hospital Regional Unimed, Brasil
2 shared publicationsCarlos José Francisco Cardoso
Hospital Naval Marcílio Dias, Brasil
2 shared publications- Cleverson Neves Zukowski
Rede D’Or São Paulo, Brasil
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (6)
Temporal Trends and In-hospital Outcomes of Transcatheter Aortic Valve Implantation in Bicuspid Aortic Valves in Brazil: A Propensity-Matched Analysis
Background: Bicuspid aortic valve (BAV) is a significant risk factor for aortic stenosis (AS). Yet, the outcomes of transcatheter aortic valve implantation (TAVI) remain unclear, as most randomized trials excluded such patients. Furthermore, most published evidence on TAVI in BAV comes from high-income countries, which may not reflect realities of underserved populations. Objectives: Evaluate temporal trends, procedural, and in-hospital outcomes between BAV and tricuspid aortic valve (TAV) patients. Methods: Retrospective observational study based on a Brazilian multicenter registry of TAVI patients between January 2009 and December 2021. We performed propensity score matching to adjust comparisons. A p-value <0.05 was considered statistically significant for all analyses. Results: Among 2,426 patients from 25 centers, 111 had BAV. TAVI procedures increased over time in both groups. After one-to-three matching, 90 BAV and 243 TAV patients were included. No significant differences were observed in rates of major vascular complications (4% vs. 5%; p=0.99), major or life-threatening bleeding (10% vs. 6%; p=0.34), stroke (2% vs. 0.4%; p=0.37), or in-hospital mortality (7% vs. 3%; p=0.21). Over time, there was a significant reduction in in-hospital mortality (p<0.01) and major procedural complications (p<0.01 for vascular, bleeding, and stroke events), regardless of valve type. Conclusion: During the study period, annual TAVI procedures increased in both BAV and TAV patients, although the prevalence of BAV remained relatively low. No significant differences were observed in procedural or clinical outcomes between the propensity-matched groups. Both valve types showed reductions in procedural complications and in-hospital mortality over time.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (6)
Open AccessTemporal Trends and In-hospital Outcomes of Transcatheter Aortic Valve Implantation in Bicuspid Aortic Valves in Brazil: A Propensity-Matched Analysis
Background: Bicuspid aortic valve (BAV) is a significant risk factor for aortic stenosis (AS). Yet, the outcomes of transcatheter aortic valve implantation (TAVI) remain unclear, as most randomized trials excluded such patients. Furthermore, most published evidence on TAVI in BAV comes from high-income countries, which may not reflect realities of underserved populations. Objectives: Evaluate temporal trends, procedural, and in-hospital outcomes between BAV and tricuspid aortic valve (TAV) patients. Methods: Retrospective observational study based on a Brazilian multicenter registry of TAVI patients between January 2009 and December 2021. We performed propensity score matching to adjust comparisons. A p-value <0.05 was considered statistically significant for all analyses. Results: Among 2,426 patients from 25 centers, 111 had BAV. TAVI procedures increased over time in both groups. After one-to-three matching, 90 BAV and 243 TAV patients were included. No significant differences were observed in rates of major vascular complications (4% vs. 5%; p=0.99), major or life-threatening bleeding (10% vs. 6%; p=0.34), stroke (2% vs. 0.4%; p=0.37), or in-hospital mortality (7% vs. 3%; p=0.21). Over time, there was a significant reduction in in-hospital mortality (p<0.01) and major procedural complications (p<0.01 for vascular, bleeding, and stroke events), regardless of valve type. Conclusion: During the study period, annual TAVI procedures increased in both BAV and TAV patients, although the prevalence of BAV remained relatively low. No significant differences were observed in procedural or clinical outcomes between the propensity-matched groups. Both valve types showed reductions in procedural complications and in-hospital mortality over time.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (6)
Tendências Temporais e Desfechos Intra-Hospitalares do Implante de Bioprótese Aórtica Transcateter em Valvas Aórticas Bicúspides no Brasil: Uma Análise Pareada por Escore de Propensão
RESUMO Fundamento: A valva aórtica bicúspide (VAB) é um fator de risco importante para estenose aórtica. No entanto, os desfechos do implante de bioprótese aórtica transcateter (TAVI) permanecem pouco claros, já que a maioria dos ensaios clínicos randomizados excluiu esses pacientes. Além disso, grande parte das evidências publicadas sobre o TAVI em VAB advém de países de alta renda, o que pode não refletir a realidade de países em desenvolvimento. Objetivos: Avaliar tendências temporais, características do procedimento e desfechos intra-hospitalares entre pacientes com VAB e valva aórtica tricúspide (VAT). Métodos: Estudo observacional retrospectivo baseado em um registro multicêntrico brasileiro de pacientes submetidos ao TAVI entre janeiro de 2009 e dezembro de 2021. Realizamos pareamento por escore de propensão para ajustar as comparações. Um valor de p<0,05 foi considerado estatisticamente significativo para todas as análises. Resultados: Entre 2426 pacientes de 25 centros, 111 tinham VAB. Os procedimentos de TAVI aumentaram ao longo do tempo em ambos os grupos. Após o pareamento na proporção de um para três, foram incluídos 90 pacientes com VAB e 243 com VAT. Não foram observadas diferenças significativas nas taxas de complicações vasculares maiores (4% vs. 5%; p=0,99), sangramento maior ou com risco de vida (10% vs. 6%; p=0,34), acidente vascular cerebral (AVC) (2% vs. 0,4%; p=0,37) ou mortalidade intra-hospitalar (7% vs. 3%; p=0,21). Ao longo do tempo, houve redução significativa na mortalidade intra-hospitalar (p<0,01) e nas principais complicações do procedimento (p<0,01 para eventos vasculares, sangramento e AVC), independentemente do tipo de valva. Conclusão: Durante o período do estudo, os procedimentos anuais de TAVI aumentaram tanto em pacientes com VAB quanto com VAT, embora a prevalência de VAB tenha permanecido relativamente baixa. Não houve diferenças significativas nos desfechos do procedimento ou clínicos entre os grupos pareados por escore de propensão, com redução das complicações do procedimento e da mortalidade para ambos os tipos de valva ao longo do tempo.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (6)
Open AccessTendências Temporais e Desfechos Intra-Hospitalares do Implante de Bioprótese Aórtica Transcateter em Valvas Aórticas Bicúspides no Brasil: Uma Análise Pareada por Escore de Propensão
RESUMO Fundamento: A valva aórtica bicúspide (VAB) é um fator de risco importante para estenose aórtica. No entanto, os desfechos do implante de bioprótese aórtica transcateter (TAVI) permanecem pouco claros, já que a maioria dos ensaios clínicos randomizados excluiu esses pacientes. Além disso, grande parte das evidências publicadas sobre o TAVI em VAB advém de países de alta renda, o que pode não refletir a realidade de países em desenvolvimento. Objetivos: Avaliar tendências temporais, características do procedimento e desfechos intra-hospitalares entre pacientes com VAB e valva aórtica tricúspide (VAT). Métodos: Estudo observacional retrospectivo baseado em um registro multicêntrico brasileiro de pacientes submetidos ao TAVI entre janeiro de 2009 e dezembro de 2021. Realizamos pareamento por escore de propensão para ajustar as comparações. Um valor de p<0,05 foi considerado estatisticamente significativo para todas as análises. Resultados: Entre 2426 pacientes de 25 centros, 111 tinham VAB. Os procedimentos de TAVI aumentaram ao longo do tempo em ambos os grupos. Após o pareamento na proporção de um para três, foram incluídos 90 pacientes com VAB e 243 com VAT. Não foram observadas diferenças significativas nas taxas de complicações vasculares maiores (4% vs. 5%; p=0,99), sangramento maior ou com risco de vida (10% vs. 6%; p=0,34), acidente vascular cerebral (AVC) (2% vs. 0,4%; p=0,37) ou mortalidade intra-hospitalar (7% vs. 3%; p=0,21). Ao longo do tempo, houve redução significativa na mortalidade intra-hospitalar (p<0,01) e nas principais complicações do procedimento (p<0,01 para eventos vasculares, sangramento e AVC), independentemente do tipo de valva. Conclusão: Durante o período do estudo, os procedimentos anuais de TAVI aumentaram tanto em pacientes com VAB quanto com VAT, embora a prevalência de VAB tenha permanecido relativamente baixa. Não houve diferenças significativas nos desfechos do procedimento ou clínicos entre os grupos pareados por escore de propensão, com redução das complicações do procedimento e da mortalidade para ambos os tipos de valva ao longo do tempo.
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (6) , 832-842
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy (ET) are the standard of care in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (aBC). Yet, disease progression remains common. In the absence of established postprogression sequencing guidelines, we conducted a pooled analysis of Kaplan-Meier (KM)–derived patient data to assess the efficacy of subsequent treatment options after disease progression on CDK4/6i therapy. METHODS: We conducted a systematic review and meta-analysis searching PubMed, Embase, Cochrane, and conference proceedings for randomized trials and cohort studies published from 2016 to December, 2023. Studies assessing subsequent treatment postprogression on CDK4/6i in patients with HR+ HER2– aBC were included. We performed a pooled analysis of KM-derived individual patient data. Outcomes of interest were progression-free survival (PFS) and overall survival (OS). This study is registered in PROSPERO, CRD42023491090. RESULTS: Of 12,895 identified records, 18 studies comprising 4,899 patients were included. Maintaining treatment with a CDK4/6i plus ET post–CDK4/6i progression was associated with longer PFS (hazard ratio [HR], 0.61 [95% CI, 0.53 to 0.70]; P < .01) and prolonged OS (HR, 0.68 [95% CI, 0.60 to 0.77]; P < .01) compared with ET monotherapy. The PFS benefit was seen in both continuing the previous CDK4/6i (HR, 0.67 [95% CI, 0.56 to 0.79]; P < .01) and switching to a different CDK4/6i (HR, 0.68 [95% CI, 0.54 to 0.85]; P < .01). Subsequent therapy with everolimus plus ET achieved similar PFS (HR, 1.10 [95% CI, 0.90 to 1.35]; P = .35) and significantly shorter OS (HR, 1.52; [95% CI, 1.21 to 1.90], P < .01) as compared with ET monotherapy. CONCLUSION: This extensive data pool suggests significant benefit of CDK4/6i regimens after disease progression as compared with ET monotherapy. Our data also support current guideline recommendations of ET-based therapies over chemotherapy for treatment sequencing.
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (6) , 832-842
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy (ET) are the standard of care in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (aBC). Yet, disease progression remains common. In the absence of established postprogression sequencing guidelines, we conducted a pooled analysis of Kaplan-Meier (KM)–derived patient data to assess the efficacy of subsequent treatment options after disease progression on CDK4/6i therapy. METHODS: We conducted a systematic review and meta-analysis searching PubMed, Embase, Cochrane, and conference proceedings for randomized trials and cohort studies published from 2016 to December, 2023. Studies assessing subsequent treatment postprogression on CDK4/6i in patients with HR+ HER2– aBC were included. We performed a pooled analysis of KM-derived individual patient data. Outcomes of interest were progression-free survival (PFS) and overall survival (OS). This study is registered in PROSPERO, CRD42023491090. RESULTS: Of 12,895 identified records, 18 studies comprising 4,899 patients were included. Maintaining treatment with a CDK4/6i plus ET post–CDK4/6i progression was associated with longer PFS (hazard ratio [HR], 0.61 [95% CI, 0.53 to 0.70]; P < .01) and prolonged OS (HR, 0.68 [95% CI, 0.60 to 0.77]; P < .01) compared with ET monotherapy. The PFS benefit was seen in both continuing the previous CDK4/6i (HR, 0.67 [95% CI, 0.56 to 0.79]; P < .01) and switching to a different CDK4/6i (HR, 0.68 [95% CI, 0.54 to 0.85]; P < .01). Subsequent therapy with everolimus plus ET achieved similar PFS (HR, 1.10 [95% CI, 0.90 to 1.35]; P = .35) and significantly shorter OS (HR, 1.52; [95% CI, 1.21 to 1.90], P < .01) as compared with ET monotherapy. CONCLUSION: This extensive data pool suggests significant benefit of CDK4/6i regimens after disease progression as compared with ET monotherapy. Our data also support current guideline recommendations of ET-based therapies over chemotherapy for treatment sequencing.
- 1 November 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (11) , 867-876
Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography in Stable Chest Pain: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: The efficacy of coronary computed tomography angiography (CCTA) versus invasive coronary angiography (ICA) among patients with stable chest pain has been studied in several trials with conflicting results. METHODS: We performed a systematic review and meta-analysis comparing CCTA first versus direct ICA among patients with stable chest pain, who were initially referred to ICA. PubMed, EMBASE, and Cochrane Central were searched for randomized controlled trials comparing the 2 strategies. Risk ratios (RRs) and mean differences with 95% CIs were computed for binary and continuous outcomes, respectively. RESULTS: Five randomized controlled trials with a total of 5727 patients were included, of whom 51.1% were referred to CCTA and 22.5% of patients had evidence of ischemia on a prior functional test. In the follow-up ranging from 1 to 3.5 years, 660 of the 2928 patients randomized to CCTA first underwent ICA (23%). Patients who underwent CCTA had lower rates of coronary revascularization (RR, 0.74 [95% CI, 0.66–0.84]; P P =0.043). Cardiovascular mortality (RR, 0.55 [95% CI, 0.24–1.23]; P =0.146), major adverse cardiovascular events (RR, 0.84 [95% CI, 0.64–1.10]; P =0.198), nonfatal myocardial infarction (RR, 1.09 [95% CI, 0.63–1.88]; P =0.768), and cardiovascular hospitalizations (RR, 0.91 [95% CI, 0.59–1.39]; P =0.669) did not differ significantly between groups. CONCLUSIONS: In patients with stable chest pain referred for ICA, CCTA avoided the need for ICA in 77% of patients otherwise referred for ICA. CCTA was associated with a reduction in the rates of coronary revascularization and stroke compared with direct ICA. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/ ; Unique identifier: CRD42023383143.
- 1 November 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (11) , 867-876
Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography in Stable Chest Pain: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: The efficacy of coronary computed tomography angiography (CCTA) versus invasive coronary angiography (ICA) among patients with stable chest pain has been studied in several trials with conflicting results. METHODS: We performed a systematic review and meta-analysis comparing CCTA first versus direct ICA among patients with stable chest pain, who were initially referred to ICA. PubMed, EMBASE, and Cochrane Central were searched for randomized controlled trials comparing the 2 strategies. Risk ratios (RRs) and mean differences with 95% CIs were computed for binary and continuous outcomes, respectively. RESULTS: Five randomized controlled trials with a total of 5727 patients were included, of whom 51.1% were referred to CCTA and 22.5% of patients had evidence of ischemia on a prior functional test. In the follow-up ranging from 1 to 3.5 years, 660 of the 2928 patients randomized to CCTA first underwent ICA (23%). Patients who underwent CCTA had lower rates of coronary revascularization (RR, 0.74 [95% CI, 0.66–0.84]; P P =0.043). Cardiovascular mortality (RR, 0.55 [95% CI, 0.24–1.23]; P =0.146), major adverse cardiovascular events (RR, 0.84 [95% CI, 0.64–1.10]; P =0.198), nonfatal myocardial infarction (RR, 1.09 [95% CI, 0.63–1.88]; P =0.768), and cardiovascular hospitalizations (RR, 0.91 [95% CI, 0.59–1.39]; P =0.669) did not differ significantly between groups. CONCLUSIONS: In patients with stable chest pain referred for ICA, CCTA avoided the need for ICA in 77% of patients otherwise referred for ICA. CCTA was associated with a reduction in the rates of coronary revascularization and stroke compared with direct ICA. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/ ; Unique identifier: CRD42023383143.